Clinical Trial Update: Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing tocilizumab with DefeROxamine plus standard treatments in ICU-admitted COVID-19 patients in Tunisia; efficacy and safety assessed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness in COVID-19
• Respiratory Distress Syndrome

Drugs mentioned

• Deferoxamine (deferoxamine)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Abderrahmane Mami Hospital | Conditions: COVID19, Intensive Care Unit | Phase 3 | Status: UNKNOWN